CN113423408A - 包含适配体作为有效成分的用于治疗及预防神经退行性疾病的组合物 - Google Patents
包含适配体作为有效成分的用于治疗及预防神经退行性疾病的组合物 Download PDFInfo
- Publication number
- CN113423408A CN113423408A CN201980073606.9A CN201980073606A CN113423408A CN 113423408 A CN113423408 A CN 113423408A CN 201980073606 A CN201980073606 A CN 201980073606A CN 113423408 A CN113423408 A CN 113423408A
- Authority
- CN
- China
- Prior art keywords
- composition
- present
- disease
- aptamer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 108091023037 Aptamer Proteins 0.000 title claims abstract description 31
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 25
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 title claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 113
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 26
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 26
- 239000011718 vitamin C Substances 0.000 claims abstract description 26
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000002011 neurocytoprotective effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 description 30
- 235000010323 ascorbic acid Nutrition 0.000 description 26
- 239000011668 ascorbic acid Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- -1 but not limited to Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000003523 substantia nigra Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000002211 L-ascorbic acid Substances 0.000 description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FBWADIKARMIWNM-UHFFFAOYSA-N N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1N=C1C=CC(=O)C=C1 FBWADIKARMIWNM-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 3
- 239000011615 dehydroascorbic acid Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003188 neurobehavioral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical class O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- PPCABZGTKJCPAH-UHFFFAOYSA-N NC1(CC(=CC=C1N)C1=CC=C(N)C=C1)N.NC1(CC(=CC=C1N)C1=CC=C(N)C=C1)N Chemical compound NC1(CC(=CC=C1N)C1=CC=C(N)C=C1)N.NC1(CC(=CC=C1N)C1=CC=C(N)C=C1)N PPCABZGTKJCPAH-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及用于治疗及预防神经退行性疾病的组合物,其包含维生素C和与上述维生素C结合的适配体的复合物作为有效成分,本发明的组合物在帕金森病实验模型中表现出改善及治疗的效果,从而具有可用作包含其的用于具有神经退行性疾病的患者的药品及保健功能食品等的效果。
Description
技术领域
本发明涉及包含与维生素C结合的适配体作为有效成分的用于治疗及预防神经退行性疾病的组合物。
背景技术
神经退行性疾病是与老化相关的疾病,其与特定神经细胞集团的逐渐丧失及蛋白质凝集相关联地定义,考虑到临床上表现的主要症状和被侵犯的脑部位,将其分为阿尔茨海默病、帕金森病、肌萎缩侧索硬化症等。这些疾病的共同特征是难以根治并且病因不明,但神经细胞的功能障碍或凋亡可能引起的氧化应激影响病因。大脑对氧化应激尤为脆弱。大脑是为保持多种功能而需要很高的金属离子浓度的器官,由于其缺乏能够处理氧化应激的能力,并且几乎没有再生能力,因此凋亡的细胞无法恢复。
因此,对能够阻止因氧化应激导致的神经细胞凋亡引起神经退行性疾病的新型治疗剂的开发的必要性日益增加。
现有专利文献
韩国公开专利公报第10-2013-0139771号
发明内容
技术问题
本发明鉴于上述必要性而提出,本发明的目的在于,提供具有治疗及预防神经退行性疾病的效果的新型组合物。
技术方案
为实现上述目的,本发明提供用于治疗及预防神经退行性疾病的组合物,其包含与维生素C结合的适配体作为有效成分。
在本发明的一实例中,优选地,上述组合物还包含维生素C,但不限于此。
在本发明的再一实例中,优选地,上述适配体由序列编号1表示的碱基序列形成,但能够通过对上述碱基序列进行一个以上的取代、缺失、移位及附加等来实现本发明效果的所有适配体序列也包括在本发明的范围内。
在本发明的另一实例中,优选地,上述维生素C与适配体的混合比的范围为10∶1至500∶1的重量比,更优选为20∶1至50∶1,但不限于此。
在本发明的一实例中,优选地,上述组合物具有神经细胞保护效果,但不限于此。
在本发明中,上述神经退行性疾病包括脑卒中、中风、痴呆、阿尔茨海默病(Alzheimer’s disease)、帕金森病(Parkinson’s disease)、亨廷顿病(Huntington’sdisease)、多发性硬化症以及肌萎缩侧索硬化症(amyotrophic lateral sclerosis)等,神经退行性疾病是指由于在脑神经系统的信息传达中非常重要的脑神经细胞的凋亡、脑神经细胞与脑神经细胞之间传达信息的突触的形成或功能上的问题、脑神经的电活动性的异常症状或减少引起的疾病。
本发明的一实施例中,优选地,上述神经退行性疾病为帕金森病,但不限于此。
本发明的药学组合物的给药途径包括口腔、静脉内、肌肉内、动脉内、骨髓内、硬膜内、心脏内、经皮、皮下、腹腔内、鼻腔内、肠管、局部、舌下或直肠,但不限于此。口服或非口服给药为优选。在本申请中使用的术语“非口服”包括皮下、皮内、静脉内、肌肉内、关节内、滑液囊内、胸骨内、硬膜内、病灶内以及头盖骨内的注射或注入技术。本发明的药学组合物还能够以用于直肠给药的栓剂的形式给药。
本发明的药学组合物能够以任何口服可接受的剂型口服给药,包括胶囊、片剂及水性悬浮液及溶液,但不限于此。在口服用片剂的情况下,包含作为通常可接受的载体的乳糖及玉米淀粉。还可以添加硬脂酸镁之类的典型的润滑剂。在以胶囊型口服给药的情况下,可以包含乳糖或干燥的玉米淀粉作为有用的稀释剂。当以水性悬浮液口服给药时,活性成分可以与乳化剂及悬浮化剂配合。可以根据需要添加甜味剂和/或风味剂和/或着色剂。
本发明的药学组合物可根据诸多因素有多种变化,包括所使用的本发明化合物的活性、年龄、体重、通常的健康状态、性别、饮食、给药时间、给药途径、排泄率、药物配合及所要预防或治疗的疾病的严重程度。本发明的药学组合物能够以丸剂、糖衣片、胶囊、液剂、凝胶、糖浆、浆液、悬浮剂来剂型化。
在本发明中,上述药学组合物可以通过与选自由钙通道阻滞剂、抗氧化剂、谷氨酸拮抗剂、抗凝剂、抗高血压剂、抗血栓剂、抗组胺剂、消炎镇痛剂、抗癌剂及抗生素组成的组中的一种以上的药剂一同制剂化或联合使用。
并且,本发明涉及食品或食品添加剂,其包含具有预防及改善神经退行性疾病的效果的Aptamin C或其药学上可接受的盐作为有效成分。
本发明的功能食品能够以各种方式使用在用于炎症预防的药剂、食品及饮料等。本发明的功能食品包括例如各种食品类、糖果、巧克力、饮料、口香糖、茶、维生素复合剂、保健辅助食品类等,能够以粉末、颗粒、片剂、胶囊或饮料等形式使用。
作为有效成分包含于本发明的功能食品的Aptamin C具有突出的氧化应激抑制活性,对于本发明所书技术领域的普通技术人员来说显而易见的是,在用于食品的情况下,会表现出突出的功效。
包含本发明的化合物的组合物可以根据通常的方法分别剂型化为散剂、颗粒剂、片剂、胶囊剂、悬浮液、乳剂、糖浆、气雾剂等口服剂型、外用剂、栓剂及灭菌注射溶液的形式来使用,作为可以包含在其中的载体、赋形剂及稀释剂,可以例举出乳糖、葡萄糖、蔗糖、山梨糖醇、甘露醇、木糖醇、赤藓糖醇、淀粉、阿拉伯胶、海藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、硬脂酸镁及矿物油。当制剂化时使用通常使用的填充剂、结合剂、湿润剂、崩解剂、表面活性剂、等稀释剂或赋形剂来配制。用于口服给药的固体制剂包括片剂、丸剂、散剂、颗粒剂、胶囊剂等,上述固体制剂通过在上述化合物中混合至少一种赋形剂,即面粉、淀粉、碳酸钙(calcium carbonate)、蔗糖(sucrose)或乳糖(lactose)、明胶等中的至少一种来配制。并且,除简单的赋形剂以外,还可以使用硬脂酸镁、滑石粉之类的润滑剂。用于口服的液体制剂有悬浮剂、内溶液剂、乳剂、糖浆剂等,除广泛用作稀释剂的水、液体石蜡以外,还可以包括多种赋形剂,例如湿润剂、甜味剂、芳香剂、保存剂等。用于非口服给药的制剂包括无菌水溶液、非水性溶剂、悬浮剂、油剂、冻结干燥剂、栓剂。非水性溶剂、悬浮剂可使用丙二醇(propylene glycol)、聚乙二醇、橄榄油之类的植物油、油酸乙酯之类的可注射酯类等。栓剂的材料可使用合成脂肪酸酯(witepsol)、聚乙二醇、吐温(tween)61、可可豆脂、月桂酯、甘油明胶等。
本发明的化合物的优选给药量根据患者的状态及体重、疾病的程度、药物形式、给药途径及期间而不同,但可以由本发明所属技术领域的普通技术人员进行适当的选择。但是,为了优选的效果,化合物以1天0.0001mg/kg至1g/kg的量给药,优选地,以1天0.001mg/kg至0.1g/kg的量给药。可以一天给药一次,也可以一天分为数次给药。上述给药量不在任何层面限制本发明的范围。
并且,本发明提供用于预防及改善神经退行性疾病的保健功能食品,其包含Aptamin C或其药学上可接受的盐作为有效成分。
包含本发明的化合物的保健功能食品能够以各种方式使用在用于预防及改善神经退行性疾病的药剂、食品及饮料等。能够添加本发明的化合物的食品形式包括糖果类的各种食品类、饮料、口香糖、茶、维生素复合剂或者保健辅助食品类食品等。
本发明的化合物能够以预防及改善神经退行性疾病为目的被添加到食品或饮料中。在此情况下,作为食品或饮料中的上述化合物的量,通过能够以食品总重量的0.01重量百分比至15重量百分比添加本发明的保健食品组合物,以100ml的饮料为基准,可以添加0.02g至10g,优选0.3g至1g的保健饮料组合物。
本发明的保健饮料组合物除了以指示的比例包含上述本发明的Aptamin C作为必要成分以外,对液体成分没有特别的限制,像普通饮料一样,还可以包含多种香味剂或天然碳水化合物等作为追加成分。上述天然碳水化合物的例包括例如葡萄糖、果糖之类的单糖,例如麦芽糖、蔗糖之类的二糖,例如糊精、环糊精之类的常见的糖以及木糖醇、山梨糖醇、赤藓糖醇之类的糖醇。作为上述之外的调味剂,还可以有利地使用天然香味剂(索马甜、甜叶菊化合物(例如甜叶菊甙A、甘草酸等))以及合成香味剂(糖精、阿巴斯甜等)。上述天然碳水化合物的比例通常为每100ml的本发明的组合物包含约1g至20g,优选地,可以包含约5g至12g。
除上述以外,本发明组合物还可以包含多种营养剂、维生素、矿物质(电解质)、合成风味剂及天然风味剂等风味剂、着色剂及填充剂(奶酪、巧克力等)、果胶酸及其盐、褐藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、酒精、碳酸饮料中使用的碳酸化剂等。
此外,本发明的组合物还可以包含用于制备天然果汁及果汁饮料及蔬菜饮料的果肉。上述成分能够以单独或组合的方式使用。上述添加剂的比例不是很重要,但可以在每100重量份的本发明的组合物中的0重量份至20重量份的范围内选择。
相对于本发明的组合物的总重量,本发明的组合物能够以0.01%至99%的重量包含上述化合物。但本发明的组合物不限于此,可根据患者的状态、疾病的种类以及病程而改变。
包含本发明的化合物的组合物还可以包含制备药学组合物时通常使用的适当的载体、赋形剂及稀释剂。
发明的效果
通过本发明可知,本发明的包含维生素C和与上述维生素C结合的适配体的复合物作为有效成分的组合物表现出神经保护效果,因此可以有效地用作神经退行性疾病的预防或治疗剂。
附图说明
图1-图3为示意性地示出基于抗坏血酸的指数富集的配体系统进化技术(SELEX)的图,图1示出维生素C具有作为被还原形式的L-抗坏血酸(L-ASCORBIC ACID)和作为被氧化形式的L-去氢抗坏血酸(L-dehydroascorbic acid)(DHA),图2示出L-抗坏血酸快速被氧化为L-去氢抗坏血酸,从而失去抗氧化能力,示出通过基于L-抗坏血酸的指数富集的配体系统进化技术发掘出作为防止L-抗坏血酸的氧化的适配体的AptaminC3T31,图3为示出抗坏血酸与AptaminC3T31结合的图,将抗坏血酸与AptaminC3T31结合的复合物称为NXP031。
图4-图5为示出抑制抗坏血酸氧化的基于荧光的微孔板法的图,图4为利用与L-去氢抗坏血酸结合来表现出荧光的邻苯二胺(OPDA)的实验结果,在使用过氧化氢处理抗坏血酸来使抗坏血酸氧化的条件下,放入AptaminC3T31来防止氧化。图5为在相同的条件下将AptaminC3T31+抗坏血酸与抗坏血酸放置8周后,利用二氯酚靛酚(DCPIP)对剩余的抗坏血酸的抗氧化能力进行比较的图。AptaminC3T31+抗坏血酸在8周后仍保持50%左右的抗氧化能力。
图6-图7为示出结合于抗坏血酸的本发明适配体的等温滴定量热(ITC,Isothermal Titration Calorimetry)特性的图,图6示出在抗坏血酸的各滴定中产生的热量的原始数据(raw data),图7示出在对滴定剂(titrant)的稀释热量进行校正后,每次滴定的合并热量。本发明的适配体与抗坏血酸之间的结合亲和度为0.9μM。
图8-图14为示出NXP031对1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)-诱导的PD小鼠模型的神经保护效果的图,在向成年C57BL/6小鼠腹腔内给药20mg/kg的1-甲基-4-苯基-1,2,3,6-四氢吡啶(4次,间隔2小时)之前,向腹腔内注射NXP031(4mg的AptaminC3T31/kg以及200mg的抗坏血酸/kg体重)或生理盐水。
图8为概述全部实验过程的图,通过向成年C57BL/6小鼠腹腔内给药20mg/kg的1-甲基-4-苯基-1,2,3,6-四氢吡啶(4次,间隔2小时)来诱导多巴胺神经细胞的破坏后,向腹腔内注射NXP031(4mg的AptaminC3T31/kg以及200mg的抗坏血酸/kg体重)来确认NXP031的神经保护效果,在第4天(Day4)进行行为学实验(爬杆试验(Pole test)、疲劳转棒实验(Rotarod test)),在第5天(Day5)将其安乐死(Sacrifice)后对中脑多巴胺神经细胞进行染色(Staining)并分析。
图9为示出各组之间的体重没有显著差异的图。
图10及图11为分别示出最后1-甲基-4-苯基-1,2,3,6-四氢吡啶给药3天后进行的爬杆试验及疲劳转棒实验的结果的图,通过爬杆试验的结果可知,比起分别单独使用维生素C(Vitamin C)、AptaminC3T31进行处理的实验组,使用NXP031进行处理的实验组的效果更为突出,与未使用1-甲基-4-苯基-1,2,3,6-四氢吡啶进行处理的空白组(Sham)相比,其恢复程度没有显著差异,统计学显著性以标记(*P<0.02vs空白组(sham);#P<0.05vs对照组(Vehicle))来表示。通过疲劳转棒实验的结果可知,比起分别单独使用维生素C(VitaminC)、AptaminC3T31进行处理的实验组,使用NXP031进行处理的实验组的效果更为突出,统计学显著性以标记(*P<0.02vs空白组(sham);#P<0.05vs对照组(Vehicle))来表示。
图12为使用通过抗酪氨酸羟化酶(anti-TH)抗体的免疫组织化学染色确认纹状体(striatum)及黑质(substantia nigra)的多巴胺神经元的结果,通过立体分析来计数TH-阳性的神经元的数量。数据以至少3次独立实验的平均数±平均数的抽样误差(S.E.M.)来表示,统计学上显著差异以标记(*P<0.02vs对照组(Control);#,§P<0.05vsMPTP)来表示。
图13为纹状体光密度(Striatal optical density)的测定结果,只有NXP031组比vehicle组显著增加。
图14为在黑质(SN)中示出TH-阳性的多巴胺神经元的数量,在黑质中计数(count)总TH-阳性细胞(Total TH-positive cell)时,可知NXP031保护了1-甲基-4-苯基-1,2,3,6-四氢吡啶对TH阳性细胞(TH positive cell)的大部分破坏。
在本附图中,将与维生素C(抗坏血酸(Ascorbic acid))结合的适配体命名为Aptamin C,尤其以AptaminC3T31来表示在实施例中使用的Aptamin C,以NXP031命名本发明的AptaminC3T31和维生素C复合物。
具体实施方式
以下,通过非限制性的实施例更为详细地说明本发明。但下述实施例仅用于例示本发明,而不应解释为本发明的范围受下述实施例的限制。
实施例1:脱氧核糖核酸适配体(DNA aptamer)的选择及序列分析
抗坏血酸的指数富集的配体系统进化技术(Ascorbic acid SELEX):
使用由~1015的独特寡核苷酸组成的脱氧核糖核酸文库(DNA library)(BasePairBiotechnologies公司)对抗坏血酸进行9轮的指数富集的配体系统进化技术。使用的缓冲液的组合如下:50mM的乙酸钠(Sodium Acetate)(pH 5.5)(Sigma公司)、1mM的氯化镁(MgCl2)(Sigma公司)、0.05%的吐温20(Tween 20)(Sigma公司)、1%的牛血清白蛋白(BSA)(Sigma公司)以及1mM的谷胱甘肽(glutathione)(Sigma公司)。通过减少适配体与靶标的结合时间,变更缓冲液的组合,并在自由分子的溶出中通过减少靶标浓度来变更指数富集的配体系统进化技术的严格性。为了在富集的(enriched)的文库中去除与氧化形式的抗坏血酸结合的适配体,执行对L-去氢抗坏血酸的阴性选择(图2)。
对通过指数富集的配体系统进化技术方法产生的富集的文库进行生物信息分析来获得候选适配体,从前20名中筛选它们在氧化中保护AA的能力。序列编号1的适配体表现出最佳效果。
实施例2:对抗坏血酸氧化产物的荧光分析
通过变形Vislisel等(Vislisel,J.M.,Schafer,F.Q.and Buettner,G.R.(2007)Analytical biochemistry,365,31-39)中记载的抗坏血酸的氧化方法来检测氧化产物去氢抗坏血酸(dehydroascorbic acid,DHA)(L-去氢抗坏血酸)并进行逆向测定。
概括如下:在添加25μM的过氧化氢(H2O2)(Sigma公司)之前,在4×的浓度下,使用AA培养基(10.3μM)在常温下培养适配体30分钟。在添加邻苯二胺染色剂(OPDA dye)(Sigma公司)之前,加入氧化剂样品后在常温下培养10分钟。使用连续光谱酶标仪读取器在激发:345nm;发射:425nm的条件下从添加染料(954.6μM)样品之后到对照组收敛时为止以每隔60秒读取一次的方式读取45分钟。为了确认筛选的数据表现出AA保护,不受氧化产物(L-去氢抗坏血酸)或分析染料(邻苯二胺)的干涉,使用在AA的位置中培养并选择的适配体对L-去氢抗坏血酸(10.3μM)(Sigma公司)反复进行荧光分析。所有分析在如下条件下进行:50mM的乙酸钠(Sigma公司)、1%的牛血清白蛋白(Sigma公司)、0.05%的吐温20(Sigma公司)、1mM的氯化镁(Sigma)、pH校正为5.5。所有荧光粉细都在黑色的384孔培养板(greinerbio-one公司)进行。每个样品反复进行3次(图4)。
实施例3:适配体增加维生素C的储存性
将本发明Aptamin C在常温下保持8周后,使用二氯酚靛酚(DCPIP,2,6-二氯苯酚吲哚酚)测定抗坏血酸的还原力。从图5可知,本发明的Aptamin C抑制抗坏血酸的氧化并保持还原力,相比于抗坏血酸单独存在的对照组,增加4倍以上的储存寿命。
实施例4:对AA的适配体滴定
为了确定最佳适配体(A)的有效浓度,将其对AA(10.3μM)进行滴定。相对于AA的适配体的相对浓度分别为10×、5×、2×、1×、0.5×、0.25×以及0.1×。在添加10.3μM的硫酸铜(CuSO4)之前,将所有适配体/AA混合物在常温下培养30分钟,在添加954.6μM的邻苯二胺之前再培养样品10分钟。在激发(ex):345nm;发射(em):425nm的条件下读取培养板45分钟,每60秒收集一次数据。每个样品反复进行3次。
从图7可知,本发明的适配体与抗坏血酸之间的结合亲和度为0.9μM。
实施例5:Aptamin C和维生素C复合物对MPP+-诱导的细胞毒性的效果
使用具有被记载的浓度的MPP+(1-甲基-4-苯基吡啶鎓(1-methyl-4-phenylpyridinium))处理SH-SY5Y细胞(人类神经母细胞瘤)后测定细胞存活率,使用NXP031(本发明的适配体和维生素C复合物)预处理上述细胞1小时后,使用5mM的MPP+暴露24小时后测定细胞存活率。通过MTT分析测定上述细胞的存活率。
实施例6:对使用1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导的帕金森病小鼠模型的效果
1-1.帕金森病小鼠模型
以20mg/kg的量使用1-甲基-4-苯基-1,2,3,6-四氢吡啶在一天内每隔2小时向体重为25g以上的8周龄的C57BL/6小鼠(mouse)的腹腔内连续注射共4次来急性地诱导帕金森病。
1-2.组合物的制备及给药
在蒸馏水中混合200mg/kg的维生素C、4mg/kg的与上述上述维生素C结合的适配体(GTGGA GGCGG TGGCC AGTCT CGCGG TGGCG GC;序列编号1)来制备组合物。在向通过上述方法诱导帕金森病的小鼠最后给药1-甲基-4-苯基-1,2,3,6-四氢吡啶1小时后,将上述组合物稀释为维生素C的最终给药浓度为200mg/Kg、Aptamin C的最终给药浓度4mg/Kg后,通过腹腔或口服向小鼠给药50μl。维生素C和Aptamin C的单独给药以与在上述组合物中相同的浓度,通过腹腔或口服给药50μl。组合物、维生素C及Aptamin C的给药以一天一次的频次连续给药4天。
1-3.神经行为学评价
为了评价通过上述方法给药1-甲基-4-苯基-1,2,3,6-四氢吡啶及组合物后诱导的神经行为学影响,在通过上述方法诱导帕金森病4周后,执行爬杆试验和疲劳转棒实验。
利用55cm高的杆进行爬杆试验。将小鼠置于杆顶,测定小鼠下降到底部的时间。
疲劳转棒实验是将小鼠放置于转棒后,启动转棒使其速度从2.5rpm开始逐渐提高至25rpm后(高速为3.5rpm~35rpm),当转棒转动时,测定从开始到小鼠失去平衡掉落地面为止的时间(秒)。
1-4.脑组织的免疫组织学染色
为了清除通过上述方法获得的脑组织切片中的内源性过氧化物酶的活性,使用1%的过氧化氢处理15分钟。然后,加入稀释为适当浓度的酪氨酸羟化酶抗体后在4℃的温度下染色一晚。通过清洗去除未结合的一次抗体后,使用生物素化(biotinylated)的第二抗体在常温下染色90分钟。通过清洗去除未结合的第二抗体后,在常温下使用ABC溶液染色1小时。使用3,3-二氨基联苯胺(3,3-diaminobenzidine)进行显色反应后通过显微镜进行观察。
从图10~图14可知,通过上述实验确认,在使用1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导帕金森病的小鼠模型的试验中,通过本发明组合物(维生素C及Aptamin C)的处置,显著减少行为学上的运动能力的缺失。并且,通过对从给予试样的小鼠中获得脑组织切片中的酪氨酸羟化酶进行免疫组织学染色来确认组织内多巴胺神经细胞的结果,确认在组合物给药组中,多巴胺神经细胞的凋亡显著减少。
Claims (7)
1.一种用于治疗及预防神经退行性疾病的组合物,其特征在于,包含与维生素C结合的适配体作为有效成分。
2.根据权利要求1所述的用于治疗及预防神经退行性疾病的组合物,其特征在于,上述组合物还包含维生素C。
3.根据权利要求1所述的用于治疗及预防神经退行性疾病的组合物,其特征在于,上述适配体由序列编号1表示的碱基序列形成。
4.根据权利要求2所述的用于治疗及预防神经退行性疾病的组合物,其特征在于,上述维生素C与适配体的混合比的范围为10t1至500t1的重量比。
5.根据权利要求1或权利要求2所述的用于治疗及预防神经退行性疾病的组合物,其特征在于,上述组合物具有神经细胞保护效果。
6.根据权利要求1或2所述的用于治疗及预防神经退行性疾病的组合物,上述神经退行性疾病选自由脑卒中、中风、痴呆、阿尔茨海默病、帕金森病、亨廷顿病、多发性硬化症以及肌萎缩侧索硬化症组成的组中。
7.根据权利要求6所述的用于治疗及预防神经退行性疾病的组合物,其特征在于,上述神经退行性疾病为帕金森病。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0140074 | 2018-11-14 | ||
KR20180140074 | 2018-11-14 | ||
KR10-2019-0055758 | 2019-05-13 | ||
KR20190055758 | 2019-05-13 | ||
PCT/KR2019/013383 WO2020101181A1 (ko) | 2018-11-14 | 2019-10-11 | 압타머를 유효성분으로 포함하는 퇴행성 뇌질환 치료 및 예방용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113423408A true CN113423408A (zh) | 2021-09-21 |
Family
ID=70732182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980073606.9A Pending CN113423408A (zh) | 2018-11-14 | 2019-10-11 | 包含适配体作为有效成分的用于治疗及预防神经退行性疾病的组合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220002729A1 (zh) |
EP (1) | EP3881849A4 (zh) |
JP (1) | JP7199534B2 (zh) |
KR (1) | KR20210060638A (zh) |
CN (1) | CN113423408A (zh) |
WO (1) | WO2020101181A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112243460A (zh) * | 2018-08-30 | 2021-01-19 | (株)纳斯摩仕 | 与l-抗坏血酸特异性结合的适配体及其用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230070674A (ko) * | 2021-11-15 | 2023-05-23 | 주식회사 넥스모스 | 신규한 압타머 및 그 압타머를 유효성분으로 포함하는 인지 기능 개선 및 항노화용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018074763A1 (ko) * | 2016-10-19 | 2018-04-26 | 주식회사 넥스모스 | 압타머를 이용한 항산화 물질의 산화 방지 방법, 물질, 그 용도 |
CN112243460A (zh) * | 2018-08-30 | 2021-01-19 | (株)纳斯摩仕 | 与l-抗坏血酸特异性结合的适配体及其用途 |
CN113164442A (zh) * | 2018-10-25 | 2021-07-23 | (株)纳斯摩仕 | 包含Aptamin-C作为有效成分的用于改善及治疗动物的脱毛、毛发损伤、皮肤疾病的组合物 |
CN113543659A (zh) * | 2019-01-15 | 2021-10-22 | 韩国食品研究院 | 包含意外片球菌的用于预防、改善或治疗神经退行性疾病的组合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
WO2011027363A2 (en) * | 2009-09-04 | 2011-03-10 | Munisekhar Medasani | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
ES2673853T3 (es) | 2012-06-05 | 2018-06-26 | Korea University Research And Business Foundation | Composición farmacéutica que contiene un derivado de verbenona para tratar o prevenir una enfermedad neurodegenerativa |
KR20170025604A (ko) * | 2015-08-31 | 2017-03-08 | 연세대학교 원주산학협력단 | 아스코르브산 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 퇴행성 신경질환 치료용 약학적 조성물 |
US10655131B2 (en) * | 2016-03-04 | 2020-05-19 | NEXMOX Co., Ltd. | Aptamer specifically binding to L-Ascorbic acid and use of the same |
WO2017150785A1 (ko) * | 2016-03-04 | 2017-09-08 | 주식회사 넥스모스 | 항산화물질의 산화방지 방법, 그 물질 및 그 용도 |
KR20190050372A (ko) * | 2017-11-03 | 2019-05-13 | 주식회사 넥스모스 | 압타머 및 항산화 물질의 복합체를 유효성분으로 포함하는 약학 조성물 |
-
2019
- 2019-10-11 CN CN201980073606.9A patent/CN113423408A/zh active Pending
- 2019-10-11 EP EP19884511.7A patent/EP3881849A4/en active Pending
- 2019-10-11 US US17/292,710 patent/US20220002729A1/en active Pending
- 2019-10-11 JP JP2021526288A patent/JP7199534B2/ja active Active
- 2019-10-11 WO PCT/KR2019/013383 patent/WO2020101181A1/ko unknown
- 2019-10-11 KR KR1020217014499A patent/KR20210060638A/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018074763A1 (ko) * | 2016-10-19 | 2018-04-26 | 주식회사 넥스모스 | 압타머를 이용한 항산화 물질의 산화 방지 방법, 물질, 그 용도 |
CN112243460A (zh) * | 2018-08-30 | 2021-01-19 | (株)纳斯摩仕 | 与l-抗坏血酸特异性结合的适配体及其用途 |
CN113164442A (zh) * | 2018-10-25 | 2021-07-23 | (株)纳斯摩仕 | 包含Aptamin-C作为有效成分的用于改善及治疗动物的脱毛、毛发损伤、皮肤疾病的组合物 |
CN113543659A (zh) * | 2019-01-15 | 2021-10-22 | 韩国食品研究院 | 包含意外片球菌的用于预防、改善或治疗神经退行性疾病的组合物 |
Non-Patent Citations (3)
Title |
---|
BARRY HORWITZ, JAMES B. ROWE: ""Functional biomarkers for neurodegenerative disorders based on the network paradigm"", 《PROGRESS IN NEUROBIOLOGY》, vol. 95, no. 4, 31 December 2011 (2011-12-31), pages 505 - 509 * |
吴佳俊;夏黑云;王小华;: "新型冠状病毒肺炎重型患者的细胞因子风暴及药物治疗研究进展", 医药导报, no. 09, 1 February 2018 (2018-02-01), pages 23 - 25 * |
张兴平;王久军;吴亚;杨华林;: "核酸适配体生物传感器在三聚氰胺检测中的应用进展", 分析试验室, no. 01, 15 January 2020 (2020-01-15), pages 11 - 12 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112243460A (zh) * | 2018-08-30 | 2021-01-19 | (株)纳斯摩仕 | 与l-抗坏血酸特异性结合的适配体及其用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2022513033A (ja) | 2022-02-07 |
US20220002729A1 (en) | 2022-01-06 |
KR20210060638A (ko) | 2021-05-26 |
EP3881849A1 (en) | 2021-09-22 |
EP3881849A4 (en) | 2022-11-09 |
JP7199534B2 (ja) | 2023-01-05 |
WO2020101181A1 (ko) | 2020-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006229533A1 (en) | Novel use of lignan compounds | |
CN113423408A (zh) | 包含适配体作为有效成分的用于治疗及预防神经退行性疾病的组合物 | |
JP2003063958A (ja) | 気分障害治療用組成物 | |
KR20160121295A (ko) | 미토콘드리아 분열 억제제를 유효성분으로 포함하는 알츠하이머성 치매 예방 또는 치료용 약학적 조성물 | |
KR102046410B1 (ko) | 강황, 모과 및 건강 추출물을 유효성분으로 함유하는 기억력 개선, 인지능력 개선, 치매 예방, 지연, 치료 또는 개선용 조성물 | |
KR20180137971A (ko) | 신경 세포사 억제 활성을 갖는 황칠 열수 추출물을 포함하는 퇴행성 신경 질환 예방 및 치료용 조성물 | |
KR102319712B1 (ko) | 찔레꽃 추출물을 유효성분으로 함유하는 기억력 개선, 인지능력 개선, 또는 치매의 예방, 지연, 치료 또는 개선용 조성물 | |
JP7106531B2 (ja) | 新規なクエルセチン系化合物を含む認知機能改善用組成物 | |
KR20190117262A (ko) | 이팝나무 잎 추출물을 유효성분으로 함유하는 기억력 개선, 인지능력 개선, 치매 예방, 지연, 치료 또는 개선용 조성물 | |
EP3210602B1 (en) | Composition for preventing or treating neurodegenerative diseases, containing ramalin | |
KR101140583B1 (ko) | 클라도니아 마실렌타 퍼플 균체 또는 이의 배양 추출물, 및/또는 이로부터 유래한 비루로퀴논을 포함하는 아세틸콜린에스테라제 저해제 | |
JP7116682B2 (ja) | 3-o-ガロイル-3,3’,5,5’,7-ペンタヒドロキシフラボンを含む認知機能改善用組成物 | |
KR20210095413A (ko) | 베타 아밀로이드의 응집으로 유발되는 질환의 예방 또는 치료용 의약 조성물 | |
KR102008774B1 (ko) | 곰피, 강황, 건강 및 홍삼 추출물을 유효성분으로 함유하는 기억력 개선, 인지능력 개선, 치매 예방, 지연, 치료 또는 개선용 조성물 | |
KR20200143490A (ko) | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 | |
KR102618160B1 (ko) | 람부탄 씨 추출물, 분획물 또는 이로부터 분리된 플라보노이드를 세노모르픽 제제의 유효성분으로 함유하는 세포의 노화 관련 증상 억제 및 노화 관련 질환을 예방 또는 치료하는 조성물 | |
KR20230149171A (ko) | 프로피오니박테리움 프레우덴레키 mj2 균주를 유효성분으로 함유하는 근육질환의 예방 또는 치료용 조성물 | |
KR101449105B1 (ko) | 큰까치수영 추출물을 포함하는 파킨슨병의 예방 및 치료용 조성물 | |
KR20220116695A (ko) | 아로니아 추출물을 포함하는 근육 질환의 예방 또는 치료용 조성물 | |
JP6974450B2 (ja) | 後発酵茶由来の新規なケンペロール系化合物を含む認知機能改善用組成物 | |
KR20210020221A (ko) | 곰취 추출물을 포함하는 조성물 | |
KR101637240B1 (ko) | 라말린을 함유하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
KR20200093803A (ko) | 진토닌을 포함하는 뇌혈관 손상에 의한 치매 예방 또는 치료용 조성물 | |
KR20240102901A (ko) | 해방풍 추출물을 유효성분으로 함유하는 근손상 질환의 예방 또는 치료용 조성물 | |
KR20230140956A (ko) | 메타세콰이어 추출물을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |